Why the study?
Elevated CA125 and NTproBNP correlate with adverse events in AHF, but their comparative and incremental prognostic usefulness needed quantification.
Does elevated CA125 add prognostic value to NTproBNP for predicting death or heart failure readmission in patients with acute heart failure?
Does elevated CA125 add prognostic value to NTproBNP for predicting death or heart failure readmission in patients with acute heart failure?
CA125 provides incremental prognostic value over NTproBNP for predicting 6-month death or rehospitalization in patients with acute heart failure.
Answers are grounded in this paper and cite their sources.
CA125 may enhance acute HF risk stratification beyond NTproBNP; leaves open prospective validation and therapeutic impact.
Background In acute heart failure (AHF), elevated carbohydrate antigen 125 (CA125) and N-terminal pro-B-type natriuretic peptide (NTproBNP) have shown to correlate with adverse events. We sought to quantify their prognostic usefulness in predicting the 6-month combined endpoint of death/heart failure readmission. Methods The study includes 352 patients admitted for AHF. The primary endpoint was 6-month combined endpoint of death / AHF rehospitalization. CA125 and NTproBNP were dichotomized according to the best cut-offs to predict 6-month primary endpoint. By multivariate Cox regression analysis, the independent association of CA125 and NTproBNP with the primary endpoint was assessed, and their incremental prognostic utility evaluated by net reclassification improvement (NRI) and integrated discrimination improvement (IDI) index. Results A total of 47 (13.4%) deaths and 113 (32.1%) AHF rehospitalizations were identified at 6-month follow-up. The subjects with CA125 ≥ 39.7 U/ml and NTproBNP ≥ 3900 pg/ml had significantly higher cumulative event rates (56.1% vs. 33.3% and 53.3% vs. 33.8%, both P < 0.001). Elevated CA125 (HR 1.93; 95%CI [1.32–2.83]; P = 0.001) was associated with higher HR than NTproBNP ≥ 3900 pg/ml (HR 1.71; 95%CI [1.19–2.48]; P = 0.004) after adjusting for established risk factors. Elevated CA125 still independently predicted adverse events when both CA125 and NTproBNP were entered together in the same multivariate model. Furthermore, risk reclassification analyses demonstrated significant improvements in NRI of 22.3% (P = 0.014) and IDI of 2.7% (P = 0.012) when adding CA125 to the base model + NTproBNP. Conclusions Elevated CA125 and NTproBNP predicted adverse outcomes in AHF patients. CA125 added prognostic value to NTproBNP, and thus, their combination conferred greater predictive capacity.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: